In part two of our AACR 2026 coverage, industry leaders were focussed on how the field is no longer constrained by data ...
Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Erasca, Inc. presented new preclinical data at the American Association ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results